Intas Pharmaceuticals Limited on FDA Import Alert List
Enforcement Report - Week of April 6, 2022
Enforcement Report - Week of November 17, 2021
Can AstraZeneca's Vaccine Prevent the Spread of COVID-19 Virus?
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceuticalncompanies over the past years.
Eugia Pharma`s Generic Anastrozole Receives Approval in US
Bob Harper and AstraZeneca Bring Virtual Series to Heart Attack Survivors to Inspire Others with Stories About Second Chances
Before it even started, ASCO 2020 was one for the books. Held virtually for the first time in its history instead of at Chicago’s massive McCormick Place conference center, the American Society of Clinical Oncology’s big meeting also shrank from five days to three last weekend.
Sovereignty, in its most distilled form, is the power to decide who will live and who must die. Both U.S. and U.K. heads of state have increasingly invoked sovereignty as a dominant discourse in their economic and foreign policies. President Trump used the words “sovereign” or “sovereignty” 21 times in his inaugural address to the United Nations General Assembly in September 2017. More recently, Prime Minister Boris Johnson characterized Britain’s exit from the European Union as “recaptured sovereignty.”
AstraZeneca today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada).